Rubicon Research Stock Price Today (NSE: RUBICON)
Fundamental Score
Rubicon Research Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Rubicon Research share price today is ₹640.20, up +0.00% on NSE/BSE as of 1 December 2025. Rubicon Research (RUBICON) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.55K (Cr). The 52-week high for RUBICON share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 68.60x, RUBICON is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 29.02% and a debt-to-equity ratio of 0.88.
Rubicon Research Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Rubicon Research Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Rubicon Research Share Price: A Financial Stability Analysis
The pharmaceutical sector, known for its robust research and development investments, often sees valuations reflecting the long-term potential of innovative drug delivery systems. This analysis examines the financial stability of Rubicon Research, with a focus on its current valuation. The Rubicon Research share price currently stands at ₹640.2, trading at a Price-to-Earnings (PE) ratio of 68.6. A key factor in assessing financial stability is comparing this valuation against its operational efficiency and peer performance.
One critical metric indicating financial health is Return on Capital Employed (ROCE). Rubicon Research boasts a ROCE of 26.16%. This high ROCE suggests efficient capital allocation and strong profitability. A consistently high ROCE like this builds a financial moat around the company. It indicates the company's competitive advantage allows it to generate higher returns than its cost of capital, allowing for reinvestment and future growth. This is a positive sign for financial stability. This can also indicate competitive cost advantages that allow the firm to retain earnings.
Comparing Rubicon Research to its peers provides further context. Competitors such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd operate in similar markets, providing a basis for relative valuation. A more established player like
Mankind Pharma Ltd may command a different valuation due to factors like management quality, brand recognition, and established distribution networks. Examining these factors is essential to determining if Rubicon Research's PE of 68.6 is justified relative to the industry.Ultimately, understanding Rubicon Research's financial stability requires a comprehensive assessment of various factors, including revenue growth, debt levels, and cash flow generation. This analysis is part of a more extensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on assessing the underlying strength and stability of the company. This aims to provide a deeper understanding of the factors influencing its valuation and future prospects. This information is for observational purposes only and should not be considered investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Rubicon Research Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RUBICON across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (29.02%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (26.16%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (56.18%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (39.19%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (37.32% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (22.95% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (59.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 68.60x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-37.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-189.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Rubicon Research Financial Statements
Comprehensive financial data for Rubicon Research including income statement, balance sheet and cash flow
About RUBICON (Rubicon Research)
Rubicon Research (RUBICON) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a curren...t market capitalisation of ₹10.55K (Cr). Rubicon Research has delivered a Return on Equity (ROE) of 29.02% and a ROCE of 26.16%. The debt-to-equity ratio stands at 0.88, reflecting the company's capital structure. Investors tracking RUBICON share price can monitor key metrics including P/E ratio, promoter holding of 59.99%, and quarterly earnings growth.
Company Details
RUBICON Share Price: Frequently Asked Questions
What is the current share price of Rubicon Research (RUBICON)?
As of 01 Dec 2025, 04:21 pm IST, Rubicon Research share price is ₹640.20. The RUBICON stock has a market capitalisation of ₹10.55K (Cr) on NSE/BSE.
Is RUBICON share price Overvalued or Undervalued?
RUBICON share price is currently trading at a P/E ratio of 68.60x, compared to the industry average of 31.77x. Based on this relative valuation, the Rubicon Research stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of RUBICON share price?
The 52-week high of RUBICON share price is ₹N/A and the 52-week low is ₹N/A. These values are updated daily from NSE/BSE price data.
What factors affect the Rubicon Research share price?
Key factors influencing RUBICON share price include quarterly earnings growth (Sales Growth: 39.19%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Rubicon Research a good stock for long-term investment?
Rubicon Research shows a 5-year Profit Growth of 22.95% and an ROE of 29.02%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.88 before investing in RUBICON shares.
How does Rubicon Research compare with its industry peers?
Rubicon Research competes with major peers in the Pharmaceuticals. Investors should compare RUBICON share price P/E of 68.60x and ROE of 29.02% against the industry averages to determine competitive standing.
What is the P/E ratio of RUBICON and what does it mean?
RUBICON share price has a P/E ratio of 68.60x compared to the industry average of 31.77x. Investors pay ₹69 for every ₹1 of annual earnings.
How is RUBICON performing according to Bull Run's analysis?
RUBICON has a Bull Run fundamental score of 44.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does RUBICON belong to?
RUBICON operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Rubicon Research share price.
What is Return on Equity (ROE) and why is it important for RUBICON?
RUBICON has an ROE of 29.02%, which indicates excellent management efficiency. ROE measures how efficiently Rubicon Research generates profits from shareholders capital.
How is RUBICON debt-to-equity ratio and what does it indicate?
RUBICON has a debt-to-equity ratio of 0.88, which indicates moderate leverage that should be monitored.
What is RUBICON dividend yield and is it a good dividend stock?
RUBICON offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Rubicon Research shares.
How has RUBICON share price grown over the past 5 years?
RUBICON has achieved 5-year growth rates of: Sales Growth 37.32%, Profit Growth 22.95%, and EPS Growth -37.89%.
What is the promoter holding in RUBICON and why does it matter?
Promoters hold 59.99% of RUBICON shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Rubicon Research.
What is RUBICON market capitalisation category?
RUBICON has a market capitalisation of ₹10547 crores, placing it in the Mid-cap category.
How volatile is RUBICON stock?
RUBICON has a beta of N/A. A beta > 1 suggests the Rubicon Research stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is RUBICON operating profit margin trend?
RUBICON has a 5-year average Operating Profit Margin (OPM) of 15.50%, indicating the company's operational efficiency.
How is RUBICON quarterly performance?
Recent quarterly performance shows Rubicon Research YoY Sales Growth of 39.19% and YoY Profit Growth of 56.18%.
What is the institutional holding pattern in RUBICON?
RUBICON has FII holding of 9.38% and DII holding of 10.54%. Significant institutional holding often suggests professional confidence in the Rubicon Research stock.